Tags

Type your tag names separated by a space and hit enter

Optimal treatment of leptospirosis: queries and projections.
Int J Antimicrob Agents. 2006 Dec; 28(6):491-6.IJ

Abstract

Although the global burden of leptospirosis remains enormous and new aspects of the disease are constantly recognised, little progress has been achieved in the field of leptospirosis therapeutics and queries regarding the utility of antibiotics in the late severe form of the disease remain. From the currently existing data, conclusions on the efficacy of antibiotic administration in severe or late disease cannot easily be drawn, since clinical trials have different selection criteria and may focus on Leptospira serovars with different virulence. However, as a rule the benefit of the doubt should apply. Moreover, new options, such as ceftriaxone, have a superior safety profile to penicillin. In vitro studies have outlined potential antimicrobial candidates such as macrolides and ketolides. Development of a globally accepted subunit vaccine for humans is warranted but is not expected in the near future.

Authors+Show Affiliations

Institute of Continuing Medical Education of Ioannina, Har. Trikoupi 10, Ioannina 45333, Greece. gpele@otenet.grNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17084067

Citation

Pappas, Georgios, and Antonio Cascio. "Optimal Treatment of Leptospirosis: Queries and Projections." International Journal of Antimicrobial Agents, vol. 28, no. 6, 2006, pp. 491-6.
Pappas G, Cascio A. Optimal treatment of leptospirosis: queries and projections. Int J Antimicrob Agents. 2006;28(6):491-6.
Pappas, G., & Cascio, A. (2006). Optimal treatment of leptospirosis: queries and projections. International Journal of Antimicrobial Agents, 28(6), 491-6.
Pappas G, Cascio A. Optimal Treatment of Leptospirosis: Queries and Projections. Int J Antimicrob Agents. 2006;28(6):491-6. PubMed PMID: 17084067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optimal treatment of leptospirosis: queries and projections. AU - Pappas,Georgios, AU - Cascio,Antonio, Y1 - 2006/11/02/ PY - 2006/08/30/received PY - 2006/08/30/accepted PY - 2006/11/7/pubmed PY - 2007/2/3/medline PY - 2006/11/7/entrez SP - 491 EP - 6 JF - International journal of antimicrobial agents JO - Int. J. Antimicrob. Agents VL - 28 IS - 6 N2 - Although the global burden of leptospirosis remains enormous and new aspects of the disease are constantly recognised, little progress has been achieved in the field of leptospirosis therapeutics and queries regarding the utility of antibiotics in the late severe form of the disease remain. From the currently existing data, conclusions on the efficacy of antibiotic administration in severe or late disease cannot easily be drawn, since clinical trials have different selection criteria and may focus on Leptospira serovars with different virulence. However, as a rule the benefit of the doubt should apply. Moreover, new options, such as ceftriaxone, have a superior safety profile to penicillin. In vitro studies have outlined potential antimicrobial candidates such as macrolides and ketolides. Development of a globally accepted subunit vaccine for humans is warranted but is not expected in the near future. SN - 0924-8579 UR - https://www.unboundmedicine.com/medline/citation/17084067/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(06)00335-9 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.